BST-2 Promotes Survival in Circulation and Pulmonary Metastatic Seeding of Breast Cancer Cells
Authors
Affiliations
Bone marrow stromal antigen 2 (BST-2) mediates various facets of cancer progression and metastasis. Here, we show that BST-2 is linked to poor survival in invasive breast cancer patients as its expression positively correlates with disease severity. However, the mechanisms that drive the pro-metastatic functions of BST-2 are not fully understood. Correlation of BST-2 expression and tumor aggressiveness was analyzed in human tissue samples. Migration, invasion, and competitive experimental metastasis assays were used to measure the cellular responses after silencing BST-2 expression. Using a mouse model of breast cancer, we show that BST-2 promotes metastasis independent of the primary tumor. Additional experiments show that suppression of BST-2 renders non-adherent cancer cells non-viable by sensitizing cells to anoikis. Embedment of cancer cells in basement membrane matrix reveals that silencing BTS-2 expression inhibits invadopodia formation, extracellular matrix degradation, and subsequent cell invasion. Competitive experimental pulmonary metastasis shows that silencing BST-2 reduces the numbers of viable circulating tumor cells (CTCs) and decreases the efficiency of lung colonization. Our data define a previously unknown function for BST-2 in the i) formation of invadopodia, ii) degradation of extracellular matrix, and iii) protection of CTCs from hemodynamic stress. We believe that physical (tractional forces) and biochemical (ECM type/composition) cues may control BST-2's role in cell survival and invadopodia formation. Collectively, our findings highlight BST-2 as a key factor that allows cancer cells to invade, survive in circulation, and at the metastatic site.
Park S, Yi E, Jeon J, Oh J, Xu Z, Park S Int J Mol Sci. 2025; 26(1.
PMID: 39796009 PMC: 11720714. DOI: 10.3390/ijms26010149.
Vascular smooth muscle cell plasticity in the tumor microenvironment.
Bell C, Baylis R, Lopez N, Ma W, Gao H, Wang F Cancer Commun (Lond). 2024; 45(2):167-171.
PMID: 39648671 PMC: 11833666. DOI: 10.1002/cac2.12635.
Yuan J, Lin M, Yang S, Yin H, Ouyang S, Xie H Heliyon. 2024; 10(10):e31137.
PMID: 38778969 PMC: 11109893. DOI: 10.1016/j.heliyon.2024.e31137.
Yu H, Bian Q, Wang X, Wang X, Lai L, Wu Z Oncol Rep. 2024; 51(3).
PMID: 38240088 PMC: 10828922. DOI: 10.3892/or.2024.8704.
Khunmanee S, Yoo J, Lee J, Lee J, Park H Mater Today Bio. 2024; 23:100867.
PMID: 38179228 PMC: 10765241. DOI: 10.1016/j.mtbio.2023.100867.